What is HC Wainwright's Estimate for AKRO FY2024 Earnings?

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - HC Wainwright decreased their FY2024 EPS estimates for shares of Akero Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($3.90) per share for the year, down from their previous estimate of ($3.44). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.82) per share. HC Wainwright also issued estimates for Akero Therapeutics' Q4 2024 earnings at ($1.13) EPS, Q1 2025 earnings at ($1.16) EPS, Q2 2025 earnings at ($1.19) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.77) EPS, FY2026 earnings at ($3.91) EPS and FY2027 earnings at ($1.17) EPS.

Akero Therapeutics Stock Down 3.9 %

Shares of AKRO traded down $1.21 during mid-day trading on Thursday, hitting $29.76. 610,606 shares of the company's stock were exchanged, compared to its average volume of 865,691. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -8.26 and a beta of -0.26. The firm has a fifty day moving average of $29.36 and a two-hundred day moving average of $25.50. The company has a quick ratio of 24.89, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics has a twelve month low of $13.86 and a twelve month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15).

Insiders Place Their Bets

In other news, insider Catriona Yale sold 15,485 shares of the company's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $32.62, for a total transaction of $505,120.70. Following the completion of the sale, the insider now owns 74,158 shares in the company, valued at approximately $2,419,033.96. This represents a 17.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Catriona Yale sold 15,485 shares of Akero Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $32.62, for a total value of $505,120.70. Following the transaction, the insider now directly owns 74,158 shares in the company, valued at approximately $2,419,033.96. The trade was a 17.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Cheng sold 1,738 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total value of $45,500.84. Following the transaction, the chief executive officer now owns 605,417 shares of the company's stock, valued at approximately $15,849,817.06. This trade represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 428,397 shares of company stock valued at $12,997,971 over the last three months. 7.94% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Janus Henderson Group PLC increased its holdings in Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company's stock valued at $154,589,000 after buying an additional 1,815,569 shares during the period. Price T Rowe Associates Inc. MD raised its position in Akero Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company's stock worth $102,569,000 after purchasing an additional 384,555 shares in the last quarter. Vanguard Group Inc. lifted its stake in Akero Therapeutics by 19.0% during the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company's stock worth $92,702,000 after purchasing an additional 584,875 shares during the period. Baker BROS. Advisors LP boosted its holdings in Akero Therapeutics by 14.6% during the first quarter. Baker BROS. Advisors LP now owns 2,713,205 shares of the company's stock valued at $68,536,000 after purchasing an additional 344,827 shares in the last quarter. Finally, Redmile Group LLC grew its stake in shares of Akero Therapeutics by 67.5% in the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company's stock valued at $46,951,000 after purchasing an additional 749,226 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.